Cargando…

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors

BACKGROUND: The β(3)-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder. However, β-adrenergic receptors are also found outside the bladder, which could lead to off-target activity. OBJECTIVE: This study assessed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brucker, Benjamin M., King, Jennifer, Mudd, Paul N., McHale, Kimberly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184556/ https://www.ncbi.nlm.nih.gov/pubmed/35693456 http://dx.doi.org/10.1016/j.curtheres.2022.100674

Ejemplares similares

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
por: Dąbrowska, Anna Maria, et al.
Publicado: (2023)

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
por: Chen, Jing Voon, et al.
Publicado: (2022)

Body‐weight‐independent glucose‐lowering effect of the β3‐adrenergic receptor agonist mirabegron in humans
por: Waki, Hironori, et al.
Publicado: (2021)

Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density
por: Yamamoto, Shota, et al.
Publicado: (2023)

Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
por: Weber, Michael A., et al.
Publicado: (2021)

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
por: Staskin, David, et al.
Publicado: (2022)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Repurposing the β(3)-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial
por: Balligand, Jean-Luc, et al.
Publicado: (2023)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Association of β2-Adrenergic Receptor Polymorphism with the Phenotype of Aspirin-Intolerant Acute Urticaria
por: Kim, Hyoun-Ah, et al.
Publicado: (2007)

Gi-protein-coupled β (1)-adrenergic receptor: re-understanding the selectivity of β (1)-adrenergic receptor to G protein : Gi-protein-coupled β (1)-adrenergic receptor
por: Chen, Hao, et al.
Publicado: (2022)

Adrenergic Response to Maximum Exercise of Trained Road Cyclists
por: Janikowska, Grażyna, et al.
Publicado: (2014)

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)

Targeting β(3)-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade
por: Cannavo, Alessandro, et al.
Publicado: (2017)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
por: Varano, Susann, et al.
Publicado: (2021)

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
por: Matsuo, Tomohiro, et al.
Publicado: (2016)

Induction of β-adrenergic metaplasticity of LTP requires intact anchoring of PKA
por: Hoffman, Janlyn R., et al.
Publicado: (2019)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus
por: Milano, Serena, et al.
Publicado: (2023)

Muscle Plasticity and β(2)-Adrenergic Receptors: Adaptive Responses of β(2)-Adrenergic Receptor Expression to Muscle Hypertrophy and Atrophy
por: Sato, Shogo, et al.
Publicado: (2011)

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial
por: Lacy, Brian E., et al.
Publicado: (2022)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

Sestrin2 Regulates Beneficial β3-Adrenergic Receptor-Mediated Effects Observed in Inguinal White Adipose Tissue and Soleus Muscle
por: Park, Min Jeong, et al.
Publicado: (2022)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Internalization Dissociates β(2)-Adrenergic Receptors
por: Lan, Tien-Hung, et al.
Publicado: (2011)

β-Adrenergic Receptor Signaling in Prostate Cancer
por: Braadland, Peder Rustøen, et al.
Publicado: (2015)

Optodynamic simulation of β-adrenergic receptor signalling
por: Siuda, Edward R., et al.
Publicado: (2015)

β-Adrenergic Receptor and Insulin Resistance in the Heart
por: Mangmool, Supachoke, et al.
Publicado: (2017)

Phosphodiesterase 4D disruption causes β2 adrenergic receptors to behave like β1 adrenergic receptors in vivo
por: Pearl, N, et al.
Publicado: (2006)

Protocol for the Stimulating β(3)-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease
por: Bubb, Kristen J, et al.
Publicado: (2021)

β-adrenergic receptor responsiveness in aging heart and clinical implications
por: Ferrara, Nicola, et al.
Publicado: (2014)

β2-adrenergic signals downregulate the innate immune response and reduce host resistance to viral infection
por: Wieduwild, Elisabeth, et al.
Publicado: (2020)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pmpk4h8vqeo1s58lc5uvnla3nv